NASDAQ$CORT
Corcept Therapeutics Incorporated · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Corcept Therapeutics reported a decrease in revenue and net income for Q4 2020, while cash and investments increased.
Corcept Therapeutics announced its Q4 and full-year 2020 financial results, with Q4 revenue at $85.7 million and GAAP net income at $26.0 million. The company's cash and investments increased to $476.9 million, and it reiterated its 2021 revenue guidance of $375 - 405 million.
- Fourth quarter revenue was $85.7 million, compared to $87.9 million in 2019.
- Fourth quarter GAAP net income was $26.0 million, compared to $29.4 million in 2019.
- Non-GAAP net income for the fourth quarter was $34.7 million, compared to $40.3 million in 2019.
- Cash and investments increased by $32.7 million in the fourth quarter, reaching $476.9 million.
Headline financials
Revenue & EPS history
Corcept Therapeutics · Revenue · Quarterly
$85.7M
Revenue by segment
Corcept Therapeutics · $103M total across 1 segment · Q2 2022
- Product Revenue$103M—100.0%
Forward guidance
Corcept Therapeutics anticipates revenue between $375 and $405 million in the next year and will initiate Phase 2 trial in patients with amyotrophic lateral sclerosis (ALS) in the fourth quarter.
Tailwinds
- Easing of public health restrictions and greater willingness of patients to visit their doctors will allow more physicians to diagnose and optimally treat patients with Cushing’s syndrome.
- Expect revenue next year of $375-405 million.
- Improving conditions should also permit more rapid progress in our clinical development programs
- Will have topline data from our ovarian and pancreatic cancer trials in the second quarter
- Plan to initiate a Phase 2 trial in patients with amyotrophic lateral sclerosis (ALS) in the fourth quarter.
Headwinds
- The COVID-19 pandemic is impacting patients, physicians, medical practice and clinical research activities.
- The availability of competing treatments, including generic versions of Korlym.
- Ability to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym.
- Risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates and oversight, and other requirements.
- The scope and protective power of our intellectual property.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.6%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+7.0%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+25.0%
Q2 2023
Best reaction
-18.5%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +10.2% | +49.1% | |
| Q4 2025 | -1.8% | -1.4% | +3.1% | |
| Q3 2025 | +7.7% | +6.2% | +21.1% | |
| Q1 2025 | -4.4% | -5.0% | -6.7% | |
| Q4 2024 | -5.6% | -11.6% | -13.8% | |
| Q3 2024 | +1.6% | +3.8% | +19.6% | |
| Q2 2024 | +1.5% | -0.8% | -3.3% | |
| Q1 2024 | +7.5% | +2.8% | +29.4% | |
| Q4 2023 | -6.2% | -6.7% | -4.0% | |
| Q3 2023 | -9.9% | -7.7% | -7.5% | |
| Q2 2023 | +25.0% | +20.9% | +32.4% | |
| Q1 2023 | +7.2% | +6.1% | +3.9% | |
| Q4 2022 | -5.2% | -8.3% | +3.3% | |
| Q3 2022 | -11.4% | -15.0% | -13.4% | |
| Q2 2022 | +1.2% | +1.3% | -8.5% | |
| Q1 2022 | -13.6% | -17.8% | -3.9% | |
| Q4 2021 | +17.5% | +15.6% | +25.9% | |
| Q3 2021 | +11.5% | +27.0% | +16.0% | |
| Q2 2021 | +1.8% | +5.8% | +5.5% | |
| Q1 2021 | -2.6% | -5.6% | -1.2% | |
| Q4 2020 | -0.5% | -5.9% | -11.2% | |
| Q3 2020 | +4.4% | +3.9% | +34.2% | |
| Q2 2020 | -6.4% | -9.2% | +24.3% | |
| Q1 2020 | +8.5% | +10.1% | +18.9% | |
| Q4 2019 | -1.8% | -3.9% | -25.9% | |
| Q3 2019 | +5.3% | +13.1% | -6.7% | |
| Q2 2019 | +11.0% | +9.9% | +12.0% | |
| Q1 2019 | -9.7% | -9.9% | -15.7% | |
| Q4 2018 | +5.3% | +12.4% | -1.1% | |
| Q3 2018 | +7.1% | +14.6% | +18.6% | |
| Q2 2018 | -5.8% | -11.4% | +5.1% | |
| Q1 2018 | -4.2% | -8.9% | +2.3% | |
| Q4 2017 | +4.5% | +0.3% | +5.9% | |
| Q3 2017 | -9.3% | -8.8% | -4.7% | |
| Q2 2017 | +7.3% | +15.0% | +33.7% | |
| Q1 2017 | -4.9% | -1.5% | +18.6% | |
| Q4 2016 | -5.3% | +11.6% | +8.5% | |
| Q3 2016 | +8.2% | +15.6% | +14.6% | |
| Q2 2016 | +1.7% | +1.2% | -7.3% | |
| Q1 2016 | -5.9% | — | — | |
| Q4 2015 | +4.3% | — | — | |
| Q3 2015 | +8.1% | — | — | |
| Q2 2015 | +8.2% | — | — | |
| Q1 2015 | -4.8% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q2 2014 | +5.0% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +1.7% | — | — | |
| Q2 2013 | -18.5% | — | — | |
| Q1 2013 | +4.3% | — | — | |
| Q4 2012 | -1.0% | — | — | |
| Q3 2012 | -18.1% | — | — | |
| Q2 2012 | -4.7% | — | — | |
| Q1 2012 | +9.2% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2011 | -4.0% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2009 | +3.3% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro